AREG and non-small cell lung carcinoma: AREG has been identified in serum of NSCLC patients; Ishikawa and colleagues suggested that circulating Amphiregulin and TGF-α could be clinically applicable as indicators for an unfavorable response to Gefitinib by identifying patients with a higher probability of drug resistance40.